These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27750344)

  • 1. [Practical aspects in the use of biosimilar insulins].
    Krämer I; Blüher M; Kuhlmann MK; Heinemann L
    Dtsch Med Wochenschr; 2016 Oct; 141(21):1565-1568. PubMed ID: 27750344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of Biosimilar Insulin Analogs: Role of Devices.
    Heinemann L; Fritz I; Khatami H; Edelman SV
    Diabetes Technol Ther; 2017 Feb; 19(2):79-84. PubMed ID: 28118050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Opportunities and challenges of extrapolation for biosimilars].
    Weise M; Wolff-Holz E
    Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar insulins.
    Heinemann L
    Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar Insulin and Costs: What Can We Expect?
    Heinemann L
    J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S; Huys I
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin biosimilars: the impact on rapid-acting analogue-based therapy.
    Franzè S; Cilurzo F; Minghetti P
    BioDrugs; 2015 Apr; 29(2):113-21. PubMed ID: 25773234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biosimilars and the efficiency principle].
    Münnch T
    Z Gastroenterol; 2016 Nov; 54(11):1230-1232. PubMed ID: 27723913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.